Loading...
XSHE
002198
Market cap248mUSD
Jul 10, Last price  
3.43CNY
1D
3.31%
1Q
-56.19%
Jan 2017
-74.55%
IPO
-4.90%
Name

Guangdong Jiaying Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002198 chart
P/E
57.12
P/S
4.54
EPS
0.06
Div Yield, %
1.51%
Shrs. gr., 5y
-0.09%
Rev. gr., 5y
-7.76%
Revenues
384m
+2.02%
66,345,31462,332,07075,247,15785,913,205104,473,155226,744,883565,820,205475,805,044449,950,867468,080,735536,983,626500,504,003544,728,978574,713,387574,713,386659,195,732659,195,732533,233,202376,167,156383,751,325
Net income
30m
+47.87%
13,721,12915,078,69525,246,95720,238,5827,568,067139,490,55173,653,93166,354,92455,172,045-214,761,68735,878,613-122,184,47519,838,3571,477,2691,477,27243,934,70343,934,70634,320,23520,611,60430,477,433
CFO
9m
-85.21%
26,367,49618,348,68610,712,98527,980,48619,695,231781,8955,271,56919,461,599103,362,81342,312,92153,126,86930,631,91762,102,73712,963,92196,873,55051,800,13227,154,40198,453,75060,848,9659,002,205
Dividend
Jun 21, 20240.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guangdong Jiaying Pharmaceutical Co., Ltd. is engaged in the comprehensive process of researching, developing, manufacturing, and marketing traditional Chinese medicines. Its operations span a vast international territory, encompassing Mainland China, Taiwan, Hong Kong, Macao, Southeast Asia, Europe, and the United States. The company primarily offers therapeutic solutions for a variety of health issues, such as throat conditions, common colds, orthopedic ailments, rheumatic diseases, gynecological disorders, conditions requiring heat-clearing, and gastrointestinal problems. These medical preparations are provided in numerous formats, including powders, tablets, capsules, granules, and pills. The distribution of its product line occurs through both independent agencies and direct sales points. The firm's operational hub is situated in Meizhou, China.
IPO date
Dec 18, 2007
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT